PolarityTE: Paradigm Shift Or Expensive Skin Graft?

About: PolarityTE, Inc. (PTE), Includes: VCEL
by: PD Research
This article is exclusive for subscribers.
PD Research
Long/short equity, biotech, small-cap, short only

SkinTE preliminary results have been showcased in Key Opinion Leader webcast.

Reimbursement appears to be a likely challenge for the product.

Logistical challenges facing similar products may limit SkinTE widespread use.

This report contains graphic pictures of wounds and injuries.

PolarityTE (COOL) recently came out with a press release stating that it expects to exceed Bloomberg consensus 3Q revenue estimates. The stated Bloomberg estimate is $350,000,